AstraZeneca Plc-Product Pipeline Review-2015

AstraZeneca Plc-Product Pipeline Review-2015

  • Products Id :- GMDHC07244CDB
  • |
  • Pages: 368
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

AstraZeneca Plc-Product Pipeline Review-2015


Global Markets Direct's, 'AstraZeneca PLC-Product Pipeline Review-2015', provides an overview of the AstraZeneca PLC's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AstraZeneca PLC's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of AstraZeneca PLC including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of AstraZeneca PLC's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the AstraZeneca PLC's pipeline products

Reasons To Buy

Evaluate AstraZeneca PLC's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of AstraZeneca PLC in its therapy areas of focus

Identify new drug targets and therapeutic classes in the AstraZeneca PLC's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of AstraZeneca PLC and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of AstraZeneca PLC

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of AstraZeneca PLC and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 7

AstraZeneca Plc Snapshot 8

AstraZeneca Plc Overview 8

Key Information 8

Key Facts 8

AstraZeneca Plc-Research and Development Overview 9

Key Therapeutic Areas 9

AstraZeneca Plc-Pipeline Review 20

Pipeline Products by Stage of Development 20

Pipeline Products-Monotherapy 21

Pipeline Products-Combination Treatment Modalities 22

Pipeline Products-Partnered Products 23

Pipeline Products-Out-Licensed Products 26

AstraZeneca Plc-Pipeline Products Glance 28

AstraZeneca Plc-Late Stage Pipeline Products 28

AstraZeneca Plc-Clinical Stage Pipeline Products 31

AstraZeneca Plc-Early Stage Pipeline Products 37

AstraZeneca Plc-Unknown Stage Pipeline Products 41

AstraZeneca Plc-Drug Profiles 42

(saxagliptin + dapagliflozin) 42

(saxagliptin + metformin hydrochloride) 44

cangrelor 46

ceftaroline fosamil 48

dapagliflozin 50

lesinurad sodium 53

naloxegol oxalate 56

propofol 58

ticagrelor 59

vandetanib 63

(aclidinium bromide + formoterol fumarate) 69

(budesonide + formoterol fumarate + glycopyrrolate) 71

(ceftazidime + avibactam sodium) 73

(dapagliflozin + metformin hydrochloride + saxagliptin) 75

(glycopyrrolate + formoterol fumarate) 77

AZD-9291 79

AZD-9291 + durvalumab 81

budesonide ER 82

cediranib maleate 83

fulvestrant 86

gefitinib 88

glycopyrrolate 93

metreleptin 95

olaparib 97

omega-3-carboxylic acids 101

PT-005 104

quetiapine fumarate ER 106

roxadustat 107

selumetinib sulfate 110

AZD-3293 113

AZD-4547 114

(abediterol + inhaled corticosteroids) 116

(aztreonam lysine + avibactam sodium) 117

(ceftaroline fosamil + avibactam sodium) 118

abediterol 119

AZD-0914 121

AZD-1775 122

AZD-1981 124

AZD-2014 125

AZD-3241 127

AZD-4017 128

AZD-4901 130

AZD-5213 131

AZD-5363 132

AZD-7624 134

AZD-9150 135

exenatide 136

exenatide Once Monthly 138

HMPL-504 140

interferon beta-1a 142

lesogaberan 144

posizolid 145

PT-008 147

PT-009 148

RDEA-3170 149

sapitinib 150

saracatinib difumarate 152

AZD-5312 154

ARC-165395XX 155

AZD-0424 156

AZD-3759 157

AZD-3965 158

AZD-6738 160

AZD-7451 162

AZD-7594 163

AZD-7986 164

AZD-8108 165

AZD-8186 166

AZD-8835 167

AZD-8999 168

AZD-9496 169

dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide 170

disufenton sodium 171

LAS-40468 174

AC-163794 175

AZ-12260493 176

AZ-12441970 177

AZ-13483342 179

AZ-4217 180

AZ-4425 181

AZ-64 182

AZ-709 183

AZ-876 184

AZD-2098 185

AZD-2858 186

AZD-3463 187

AZD-3857 188

AZD-9708 189

AZGHS-22 190

AZGHS-38 191

Cephalosporin + Beta-Lactamase Inhibitor 192

CWGNC-41 193

Drug 1 for Cancer 194

Drug 2 for Cancer 195

Drug 3 for Cancer 196

Drug 4 for Cancer 197

Drug 5 for Cancer 198

Drug 6 for Cancer 199

Drugs 1 for Cancer 200

Drugs 2 for Cancer 201

KU-0060648 202

KU-59403 203

LAS-191351 204

LAS-194871 205

MMV-253 206

Monoclonal Antibody Conjugates for Cancer 207

NBTI-5463 208

NKTR-119 209

PL-8905 210

R-256 211

Small Molecule to Antagonize GPR103 for Obesity 212

Small Molecule to Antagonize Histamine 3 Receptor for Cognition 213

Small Molecule to Antagonize Sphingosine 1 Phosphate Receptor 1 for Oncology 214

Small Molecule to Block Kv1.5 for Atrial Fibrillation 215

Small Molecule to Inhibit DNA Gyrase for Streptococcal Pneumonia 216

Small Molecule to Inhibit PI3K Beta for Bleeding and Clotting Disorders 217

Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia 218

Small Molecules for Dyslipidemia and Hypertriglyceridemia 219

Small Molecules for Malaria 220

Small Molecules to Antagonize M3 Receptors for Respiratory Disorders 221

Small Molecules to Antagonize P2X3 for Chronic Pain 222

Small Molecules to Inhibit CDK9 for Inflammatory Pain and Rheumatoid Arthritis 223

Small Molecules to Inhibit DNA GyrB for Tuberculosis 224

Small Molecules to Inhibit DprE1 for Mycobacterium Tuberculosis 225

AZ-10047130 226

AZ-27 227

AZ-465 228

AZ-82 229

AZD-3147 230

Drugs for Cardiovascular Diseases 231

HD-001 232

Small Molecule 1 for Malaria 233

Small Molecule to Inhibit 11beta-HSD-1 for Type 2 Diabetes 234

Small Molecule to Inhibit Src Tyrosine Kinase for Lymphangioleiomyomatosis 235

Small Molecules for Cancer 236

Small Molecules for Tuberculosis 237

Small Molecules to Inhibit Acetohydroxyacid Synthase for Mycobacterium Infections 238

Small Molecules to Inhibit ATP Synthesis for Tuberculosis 239

Small Molecules to Inhibit Carboxypeptidase U for Thrombosis 240

Small Molecules to Inhibit DNA Gyrase B for Tuberculosis 241

Small Molecules to Inhibit DXP-Reductoisomerase for Malaria 242

Small Molecules to Inhibit MALT-1 for Oncology and Immunology 243

Small Molecules to Inhibit p38 MAP Kinase for Inflammatory Diseases 244

Small Molecules to Inhibit PLA2 for Undisclosed Indication 245

Small Molecules for Diabetic Nephropathy 246

AstraZeneca Plc-Pipeline Analysis 247

AstraZeneca Plc-Pipeline Products by Target 247

AstraZeneca Plc-Pipeline Products by Route of Administration 252

AstraZeneca Plc-Pipeline Products by Molecule Type 253

AstraZeneca Plc-Pipeline Products by Mechanism of Action 254

AstraZeneca Plc-Recent Pipeline Updates 258

AstraZeneca Plc-Dormant Projects 315

AstraZeneca Plc-Discontinued Pipeline Products 319

Discontinued Pipeline Product Profiles 324

AstraZeneca Plc-Company Statement 344

AstraZeneca Plc-Locations And Subsidiaries 346

Head Office 346

Other Locations & Subsidiaries 346

AstraZeneca Plc-Key Manufacturing Facilities 352

Appendix 353

Methodology 353

Coverage 353

Secondary Research 353

Primary Research 353

Expert Panel Validation 353

Contact Us 353

Disclaimer 354

List of Tables

AstraZeneca Plc, Key Information 22

AstraZeneca Plc, Key Facts 22

AstraZeneca Plc-Pipeline by Indication, 2015 24

AstraZeneca Plc-Pipeline by Stage of Development, 2015 34

AstraZeneca Plc-Monotherapy Products in Pipeline, 2015 35

AstraZeneca Plc-Combination Treatment Modalities in Pipeline, 2015 36

AstraZeneca Plc-Partnered Products in Pipeline, 2015 37

AstraZeneca Plc-Partnered Products/ Combination Treatment Modalities, 2015 38

AstraZeneca Plc-Out-Licensed Products in Pipeline, 2015 40

AstraZeneca Plc-Out-Licensed Products/ Combination Treatment Modalities, 2015 41

AstraZeneca Plc-Pre-Registration, 2015 42

AstraZeneca Plc-Phase III, 2015 43

AstraZeneca Plc-Phase II, 2015 45

AstraZeneca Plc-Phase I, 2015 48

AstraZeneca Plc-Preclinical, 2015 51

AstraZeneca Plc-Discovery, 2015 54

AstraZeneca Plc-Unknown, 2015 55

AstraZeneca Plc-Pipeline by Target, 2015 261

AstraZeneca Plc-Pipeline by Route of Administration, 2015 266

AstraZeneca Plc-Pipeline by Molecule Type, 2015 267

AstraZeneca Plc-Pipeline Products by Mechanism of Action, 2015 268

AstraZeneca Plc-Recent Pipeline Updates, 2015 272

AstraZeneca Plc-Dormant Developmental Projects,2015 329

AstraZeneca Plc-Discontinued Pipeline Products, 2015 333

AstraZeneca Plc, Subsidiaries 360

AstraZeneca Plc, Key Manufacturing Facilities 366

List of Figures

AstraZeneca Plc-Pipeline by Top 10 Indication, 2015 24

AstraZeneca Plc-Pipeline by Stage of Development, 2015 34

AstraZeneca Plc-Monotherapy Products in Pipeline, 2015 35

AstraZeneca Plc-Combination Treatment Modalities in Pipeline, 2015 36

AstraZeneca Plc-Partnered Products in Pipeline, 2015 37

AstraZeneca Plc-Out-Licensed Products in Pipeline, 2015 40

AstraZeneca Plc-Pipeline by Top 10 Target, 2015 261

AstraZeneca Plc-Pipeline by Top 10 Route of Administration, 2015 266

AstraZeneca Plc-Pipeline by Top 10 Molecule Type, 2015 267

AstraZeneca Plc-Pipeline Products by Top 10 Mechanism of Action, 2015 268

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of AstraZeneca PLC; AstraZeneca PLC - Key Therapeutics; AstraZeneca PLC - Pipeline Overview and Promising Molecules; AstraZeneca PLC - News; AstraZeneca PLC - Latest Updates; AstraZeneca PLC - Pipeline; AstraZeneca PLC - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 101595
Site License
USD 3000 INR 203190
Corporate User License
USD 4500 INR 304785



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]